Modality
Degrader
MOA
SOS1i
Target
BCL-2
Pathway
JAK/STAT
LGSHeart Failure
Development Pipeline
Preclinical
Aug 2019
→ Nov 2025
PreclinicalCurrent
NCT04460640
408 pts·LGS
2022-08→TBD·Active
NCT07163533
1,107 pts·Heart Failure
2019-08→2025-11·Terminated
1,515 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-164mo agoInterim· Heart Failure
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Termina…
Preclinical
Active
Catalysts
Interim
2025-11-16 · 4mo ago
Heart Failure
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04460640 | Preclinical | LGS | Active | 408 | OS |
| NCT07163533 | Preclinical | Heart Failure | Terminated | 1107 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |